Fey, T., Kasprzak, J., Ernst, J., Weiher, F., Schmid, M. et al. (2025). "Information and support for cancer patients and their relatives - evaluation of central contract point enquiries: a retrosprective analysis. BMC Health 1192.

Möhrmann, L, Werner, M., Oles`M., Mock, A., Uhrig, S., Jahn, et al. (2022). Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity. Nat Commun. 4485.

Tejada-Lapuerta, A., Schaar, A.C., Gutgesell, R., Palla, G., et al. (2025). Nicheformer: a foundation model for single-cell and spatial omics. Nat Methods. 2525-2538.

Falcomatà, C., Bärthel, S., Widholz S.A., Schneeweis, C., Montero J., et al. (2022). Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. 318-336.

Papargyriou, A., Najajreh, M., Cook, D., Maurer, C., Bärthel, S., et al. (2025). Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Nat Biomed Eng. 836-864.

 Wartewig, T., Daniels, J., Schulz, M., Hameister, E. Joshi, A., et al. (2023). PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nat Cancer. 1508-1525.

Rieger, L., Irlinger, K., Füchsl, F., Tietje, M., Purcarea, A., et al. (2026). Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens. Blood. 534-546.

Braitsch, K., Lorenzini, T., Hefter, M., Koch, K., Nickel, K., et al. (2025). CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia. Theranostics. 1838-7640.

Hager, P., Jungmann, F., Holland, R., Bhagat, K., Hubrecht, I., et al. (2024). Evaluation and mitigation of the limitations of large language models in clinical decision-making. Nat Med. 2613-2622.